

Manual preliminary application form MLDS Spijsverteringskankers 2018

Refer to the 'Subsidievoorwaarden MLDS Spijsverteringskankers 2018' (available at www.mlids.nl/wetenschappelijk-onderzoek/subsidiewijzer) for more information.

Procedure

One copy of the complete preliminary protocol form in WORD format is sent to research@mlids.nl before **Monday April 2th 2018, 12:00 noon**. This copy includes digital signatures.

Guidelines for filling in the preliminary application form

General

- Fill in the form in English and do not exceed the maximum of 4 pages. Signatures (point II) are allowed on an extra page. Use font Arial, size 10; for references Arial, size 8 is allowed, the form will do this automatically.
- Do not send appendices with your application as these will not be included into the judging process.
- The cells of the table should allow you to use more space than is indicated. If the cells do not become larger when needed; proceed as follows: move cursor to the cell > click right mousebutton > choose 'tabeleigenschappen' > select tabblad 'rij' > check the box 'rij eventueel splitsen bij nieuwe pagina'.
- Incomplete forms or forms to which the guidelines are not applied will not be taken into consideration.
- Hyperlinks are not allowed.

Explanation to some questions on the form

1. Fill in the name of the project leader, including title(s) and the name and address of the applying institute. This address will be used for correspondence. The project leader can only be one person and is responsible for the project. Correspondence will be addressed to the project leader. The project leader must have a position at the applying research institute for the duration of the project and must have a PhD degree.

4. Specify the type of research, either clinical or translational. Furthermore, indicate the disease and related organs your proposed study will focus on.

5. Do not exceed the maximum of 300 words.

In the case of patient-related research, we would like to refer you to the 'Consolidation of the standards of reporting trials' (CONSORT) checklist, which is published in JAMA, The Lancet and the British Medical Journal. Following this model will help you to cover all the issues involved with a trial.

6. This abstract will be used by patients to review the proposal. Do not use abbreviations or technical language.

The abstract must conform to the following conditions:

- Within the paragraph Objective please answer the following questions:
 - Which problem will be solved by this proposal?
 - Why is it important for patients that this problem is solved?
 - How extensive is the problem in the Netherlands?
- Within the paragraph Methods please the methods that will be used in the study.
- Within the paragraph Anticipated results please describe the expected results in a realistic manner
- Within the paragraph Anticipated results please answer the following question:
 - What will be noticeable for the patient within the next three to five years?

7. State the hypothesis/ hypotheses of the study.
8. Describe in more detail the methods that will be used in the study.
9. Give an overview of the work plan for each year the grant is applied for. You are obliged to include at least a power calculation to establish the patient number needed.
10. Outline the importance of the proposed research for the prevention and treatment of digestive disorders.
11. List five relevant publications concerning this application.
12. State in broad terms what resources will be required to conduct the proposed research. The cost estimates should cover the entire period of the grant. List the nature of the post and both the intensity of the appointment (in fte – full equivalent) and the total duration of the appointment. The maximum of the MLDS Spijsverteringskankers is €250.000 spread over a period of maximum 4 years.

Report whether and how much financial support from others has been requested or received. In the case that this is requested, one should indicate when a decision is to be expected and under what conditions this grant is or will be assigned. If not requested, this should be explicitly reported.

13. The digital signature of the project leader should be included. With this signature the project leader declares the following: “I certify that the statements herein are true, complete and accurate to the best of my knowledge. I agree with the grant conditions 2018”.

The digital signatures of all other members of the project group and of the head of the department/institute should be included. These signatures indicate agreement with the grant conditions 2018 of the Maag Lever Darm Stichting.